What is HC Wainwright’s Forecast for BEAM Q1 Earnings?

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Beam Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.90) per share for the quarter. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.85) EPS, Q4 2027 earnings at ($0.87) EPS and FY2030 earnings at ($1.37) EPS.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings data on Tuesday, February 24th. The company reported $2.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $3.46. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The business had revenue of $114.11 million during the quarter, compared to analyst estimates of $13.22 million. During the same quarter in the previous year, the firm posted ($1.09) EPS. The business’s revenue for the quarter was up 280.3% compared to the same quarter last year.

A number of other research firms have also issued reports on BEAM. Tudor Pickering set a $41.00 target price on shares of Beam Therapeutics in a research note on Wednesday, January 21st. Wedbush boosted their price objective on Beam Therapeutics from $57.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group started coverage on shares of Beam Therapeutics in a research note on Friday, February 20th. They set a “buy” rating and a $74.00 price objective on the stock. Sanford C. Bernstein upped their price objective on shares of Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Finally, Evercore began coverage on shares of Beam Therapeutics in a research note on Monday, November 24th. They set an “outperform” rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.19.

Beam Therapeutics Stock Performance

Shares of BEAM opened at $27.44 on Wednesday. The firm has a fifty day moving average of $28.91 and a 200-day moving average of $25.40. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -27.17 and a beta of 2.12. Beam Therapeutics has a 1 year low of $13.52 and a 1 year high of $36.44.

Insider Activity

In other news, insider Christine Bellon sold 18,629 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $34.61, for a total transaction of $644,749.69. Following the sale, the insider directly owned 97,038 shares of the company’s stock, valued at $3,358,485.18. The trade was a 16.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Beam Therapeutics

Institutional investors have recently bought and sold shares of the stock. CWM LLC lifted its stake in Beam Therapeutics by 15.4% during the fourth quarter. CWM LLC now owns 2,466 shares of the company’s stock valued at $68,000 after buying an additional 329 shares in the last quarter. Wealth Effects LLC raised its holdings in shares of Beam Therapeutics by 4.3% during the fourth quarter. Wealth Effects LLC now owns 9,600 shares of the company’s stock valued at $266,000 after acquiring an additional 400 shares during the period. Franklin Resources Inc. lifted its position in shares of Beam Therapeutics by 2.6% in the 4th quarter. Franklin Resources Inc. now owns 21,948 shares of the company’s stock valued at $608,000 after acquiring an additional 566 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Beam Therapeutics by 2.2% in the 3rd quarter. Arizona State Retirement System now owns 26,771 shares of the company’s stock valued at $650,000 after acquiring an additional 580 shares in the last quarter. Finally, Van ECK Associates Corp boosted its stake in Beam Therapeutics by 48.7% in the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock worth $52,000 after purchasing an additional 707 shares during the period. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.